Videnskabelig årsrapport 2005 - Rigshospitalet

Finsencentret
mutation. J Cell Biochem
2005;96:412-27.
Pedersen MW, Pedersen N, Ottesen LH,
Poulsen HS. Differential response to
gefitinib of cells expressing normal
EGFR and the mutant EGFRvIII. Br J
Cancer 2005;93:915-23.
Pedersen N, Hansen S, Heydenreich AV,
Kristensen HG, Poulsen HS. Solid
lipid nanoparticles can effectively
bind DNA, streptavidin and
biotinylated ligands. EurJ Pharm
Biopharm 2006;62:155-62.
Pedersen N, Pedersen MW, Lan MS,
Breslin MB, Poulsen HS. The
insulinoma-associated 1: a novel
promoter for targeted cancer gene
therapy for small-cell lung cancer.
Cancer Gene Ther 2005;13(4):375-
84.
Piccart-Gebhart MJ, Procter M, Leyland-
Jones B, Goldhirsch A, Untch M,
Smith I, et al. Trastuzumab after
adjuvant chemotherapy in HER2-
positive breast cancer. N Engl J Med
2005;353:1659-72.
Poulsen TT, Pedersen N, Perin MS,
Hansen CK, Poulsen HS. Specific
sensitivity of small cell lung cancer
cell lines to the snake venom toxin
taipoxin. Lung Cancer 2005;50:329-
37.
Poulsen TT, Pedersen N, Poulsen HS.
Replacement and suicide gene
therapy for targeted treatment of lung
cancer. Clin Lung Cancer
2005;6:227-36.
Travis LB, Hill D, Dores GM,
Gospodarowicz M, van Leeuwen FE,
Holowaty E, et al. Cumulative
absolute breast cancer risk for young
women treated for Hodgkin
lymphoma. J Natl Cancer Inst
2005;97:1428-37.
Reumatologisk Klinik
Videnskabeligt personale
Seniorforskere
Overlæge, ph.d.Bo Baslund
Afdelingslæge Per Brown Frandsen
Afdelingslæge Anette Hansen
Klinichef, dr.med. Søren Jacobsen
Afdelingslæge Lars Juul
Afdelingslæge Niels Tvede
Andre forskere
Klinisk assistent Lone Troelsen
Vigtigste satsningsområder
inden for forskningen
Kohorteundersøgelser af flere
reumatologiske patientgrupper
herunder reumatoid artrit, systemisk
lupus erythematosus, antifosfolipid
antistofsyndrom, sklerodermi,
neurosarkoidose og Wegeners
granulomatose.
Forskningen retter sig primært mod disse
kohorter i form af klinisk forskning
understøttet af laboratorieforskning
med undersøgelser af forskellige
inflammatoriske og serologiske
biomarkører.
Publikationer
A. Førsteforfatter fra
forskningsenheden
Baslund B, Tvede N, Danneskiold-
Samsoe B, Larsson P, Panayi G,
Petersen J, et al. Targeting
interleukin-15 in patients with
rheumatoid arthritis: a proof-ofconcept
study. Arthritis Rheum
2005;52(9):2686-92.
Baslund B, Dalhoff KP, Schmiegelow K.
[Individual monitoring of thiopurine
and methotrexate treatment]. Ugeskr
Laeger 2005;167(20):2177-9.
B. Medforfatter fra forskningsenheden
Hetland ML, Unkerskov J, Ravn T, Friis
M, Tarp U, Andersen LS, Hansen A,
et al. Routine database registration of
biological therapy increases the
reporting of adverse events
twentyfold in clinical practice. First
results from the Danish Database
(DANBIO). Scand J Rheumatol
2005;34(1):40-4.
Jørgensen CS, Hansen KB, Jacobsen S,
Halberg P, Ullman S, Hansen D, et
al. Absence of high-affinity
calreticulin autoantibodies in patients
with systemic rheumatic diseases and
coeliac disease. Scand J Clin Lab
Invest 2005;65(5):403-12.
Mackiewicz Z, Rimkevicius A, Petersen
J, Andersen CB, Dudek E, Vytrasova
M, et al. Macrophages overloaded
with tissue debris in Wegener's
granulomatosis. Ann Rheum Dis
2005;64(8):1229-32.
Nordenbaek C, Johansen JS, Halberg P,
Wiik A, Garbarsch C, Ullman S, et
al. High serum levels of YKL-40 in
patients with systemic sclerosis are
associated with pulmonary
involvement. Scand J Rheumatol
2005;34(4):293-7.
Østergaard M, Duer A, Nielsen H,
Johansen JS, Narvestad E, Ejbjerg
BJ, et al. Magnetic resonance
imaging for accelerated assessment of
drug effect and prediction of
subsequent radiographic progression
in rheumatoid arthritis: a study of
patients receiving combined anakinra
and methotrexate treatment. Ann
Rheum Dis 2005;64(10):1503-6.
Strålebiologisk
Laboratorium
Videnskabeligt personale
Seniorforskere
Overlæge, dr.med. Hans Skovgaard
Poulsen
Ph.d.-studerende
Cand.scient. Thomas Tuxen Poulsen
Andre forskere
Cand.scient, ph.d. Mikkel Wandahl
Pedersen
Lic.scient. Nina Pedersen
Resevelæge Benedikte Hasselbalch
Cand.scient. Alice Bjerregaard
Cand.scient Rosa Zandi
Studenterforskere
Stud.scient. Peter Andersen,
specialestuderende
Stud.scient. Rober Dagil,
specialestuderende
Øvrigt forskningspersonale
Pia Pedersen, bioanalytiker
Mette Villingshøj, bioanalytiker
Vigtigste satsningsområder
inden for forskningen
Betydningen af en overekspression af
EGF receptoren og en cancerspecifik
receptor (EGFRvIII) for udvikling og
opretholdelse af den maligne
fænotype.
Transkriptionel targeteret genterapi mod
småcellet lungecancer.
Publikationer
Videnskabelige artikler
A. Førsteforfatter fra
forskningsenheden
Pedersen MW, Pedersen N, Damstrup L,
Villingshøj M, Sønder SU, Rieneck
K, et al. Analysis of the epidermal
growth factor receptor specific
transcriptome: effect of receptor
expression level and an activating
mutation. J Cell Biochem
2005;96(2):412-27.
Pedersen MW, Pedersen N, Ottesen LH,
Poulsen HS. Differential response to
gefitinib of cells expressing normal
EGFR and the mutant EGFRvIII. Br J
Cancer 2005;93(8):915-23.
Poulsen TT, Pedersen N, Poulsen HS.
Replacement and suicide gene
therapy for targeted treatment of lung
cancer. Clin Lung Cancer
2005;6(4):227-36.
Poulsen TT, Pedersen N, Perin MS,
Hansen CK, Poulsen HS. Specific
sensitivity of small cell lung cancer
cell lines to the snake venom toxin
taipoxin. Lung Cancer
2005;50(3):329-37.
B. Medforfatter fra forskningsenheden
Christensen HC, Schuz J, Kosteljanetz M,
Poulsen HS, Boice JD, Jr.,
McLaughlin JK, et al. Cellular
telephones and risk for brain tumors:
a population-based, incident casecontrol
study. Neurology
2005;64(7):1189-95.
Patenter
Lan, MS, Breslin, MB, Pedersen N,
Pedersen MW, Poulsen HS
Insulinoma Associated-1 promoterspecific
therapy of neuroendocrine
tumors. Patent no. PTO 60/700,397.
Submitted 2005.
Videnskabelig årsrapport 33